"Pay-to-Participate" Stem Cell Studies: How to Tell a Real Clinical Trial From a Marketing Exercise

Not every listing on ClinicalTrials.gov represents the kind of rigorously overseen research most people picture when they hear "clinical trial." Bioethics researchers have documented a pattern in which stem cell businesses register studies on the federal registry that require patients to pay substantial out-of-pocket fees simply to "enroll" — a structure that differs sharply from how legitimate, cost-justified trial charges work. This piece explains what that research found, how authentic participant charges are supposed to be authorized, and what questions can help you tell the two apart before you commit money or hope to a listed "study."

What Researchers Found When They Looked Closely at the Registry

In a 2017 analysis published in the peer-reviewed journal Regenerative Medicine, bioethicist Leigh Turner of the University of Minnesota examined stem cell–related studies listed on ClinicalTrials.gov, the NIH's public trial registry. He identified 18 stem cell studies that charged participants to take part: 7 were explicitly described as "patient-funded" or "patient-sponsored," while 11 others did not use that language but still required patients to pay. Turner concluded that many of these listings "look like little more than marketing exercises" rather than hypothesis-driven research, citing methodological weaknesses and apparent gaps in regulatory compliance. His concern was not simply that money changed hands, but that the registry listing itself was being used to lend an unearned appearance of scientific legitimacy to direct-to-consumer treatment offerings. This fits a broader pattern: in a 2016 study in Cell Stem Cell, Turner and stem cell biologist Paul Knoepfler catalogued more than 570 U.S. businesses marketing unproven stem cell interventions directly to consumers, underscoring how large this landscape had already become.

Why a Listing on ClinicalTrials.gov Isn't a Stamp of Approval

It's worth understanding what registry inclusion actually certifies, because the gap between appearance and substance is where confusion sets in. ClinicalTrials.gov accepts studies based on information submitted by the study's own sponsor; the registry does not independently verify that a study is well-designed, ethical, or safe before posting it, and the site carries language making clear that a listing does not mean the government has evaluated or endorsed the study. In other words, a professional-looking registry number can sit atop a study that never received meaningful outside scrutiny. Turner has argued that NIH's existing disclaimer is not a strong enough safeguard and has called for more active vetting, flagging, or removal of questionable listings. As of recent reporting, NIH has said it is evaluating options beyond the disclaimer but has not described a specific new vetting process.

When Charging Research Participants Is Actually Legitimate

Participant payment in research isn't inherently improper — but legitimate cost recovery is narrow, documented, and time-limited. Under FDA rules governing investigational new drug (IND) applications, a sponsor generally must obtain FDA authorization before charging for an investigational product used in a trial, must justify the specific amount charged, and — for the sponsor's own product — must have an independent certified public accountant (someone with no employment relationship to the company) confirm that the cost calculation is accurate. These charging authorizations expire and must be renewed, and they're meant to offset manufacturing or logistics costs, not to fund the business model of selling access to treatment. A legitimate research charge, in short, comes with a paper trail that a prospective participant can ask about.

Questions That Help Separate the Two

• Is the fee framed as reimbursing documented costs (with a published rationale), or is it simply the clinic's price for the "treatment" itself?
• Does the listing disclose, clearly and prominently, that participants are required to pay — or is that buried or absent?
• Is there independent institutional review board (IRB) oversight distinct from the business offering the treatment, and can the clinic describe it specifically?
• Is the study designed to test a hypothesis with a control or comparison arm, or is every enrolled patient simply receiving the product being sold?
• Has the sponsor published any results, anywhere, from prior cohorts — or does the "trial" structure appear to exist primarily to describe paying customers as "research participants"?

Bottom Line

A study number on ClinicalTrials.gov signals that a sponsor submitted information to a federal registry — not that independent experts vetted the science, the ethics, or the safety of what's being offered. Published bioethics research has documented real cases of stem cell businesses charging patients substantial fees to "enroll" in studies that function more like marketing than research. Legitimate cost recovery in FDA-regulated trials exists, but it's bounded by specific authorization, documentation, and accountant review — not simply a price tag attached to a registry listing. Before paying to "participate" in any stem cell study, it's reasonable to ask for the IRB's name, the FDA authorization for any charge, and whether comparable past results have been published anywhere outside the clinic's own marketing.